Clinical Trials Logo

Lymphoproliferative Disorder clinical trials

View clinical trials related to Lymphoproliferative Disorder.

Filter by:

NCT ID: NCT00516503 Completed - Pain Clinical Trials

Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

Start date: February 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: Baclofen-amitriptyline-ketamine (BAK) gel may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether BAK gel is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy . PURPOSE: This randomized phase III trial is studying BAK gel to see how well it works compared with a placebo in treating peripheral neuropathy caused by chemotherapy in patients with cancer.

NCT ID: NCT00499668 Withdrawn - Lymphoma Clinical Trials

Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer

Start date: August 2007
Phase: N/A
Study type: Interventional

RATIONALE: Antiemetic drugs, such as aprepitant and ondansetron, may help lessen nausea and vomiting caused by opioids. It is not yet known whether aprepitant is more effective than ondansetron in treating nausea and vomiting caused by opioids in patients with cancer. PURPOSE: This randomized clinical trial is studying aprepitant to see how well it works compared to ondansetron in treating nausea and vomiting caused by opioids in patients with cancer.

NCT ID: NCT00436618 Completed - Lymphoma Clinical Trials

Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Start date: August 2005
Phase: Phase 2
Study type: Interventional

RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying the side effects and how well everolimus works in treating patients with lymphoma that has relapsed or not responded to previous treatment.

NCT ID: NCT00424242 Completed - Lymphoma Clinical Trials

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

Start date: January 2007
Phase: Early Phase 1
Study type: Interventional

RATIONALE: Pemetrexed disodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Studying samples of cerebrospinal fluid and blood from patients with cancer in the laboratory may help doctors learn how pemetrexed disodium works in the body and identify biomarkers related to cancer. PURPOSE: This clinical trial is studying the side effects and how well pemetrexed disodium works in treating patients with leptomeningeal metastases.

NCT ID: NCT00416624 Completed - Lymphoma Clinical Trials

Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy

Start date: May 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Epoetin alfa and darbepoetin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with cancer. PURPOSE: This randomized clinical trial is studying four different schedules of epoetin alfa or darbepoetin alfa to compare how well they work in treating patients with anemia caused by chemotherapy.

NCT ID: NCT00387530 Withdrawn - Lymphoma Clinical Trials

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

Start date: May 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: The Epstein-Barr virus can cause cancer and lymphoproliferative disorders. Valganciclovir is an antiviral drug that acts against the Epstein-Barr virus. Phenylbutyrate may make cells infected with Epstein-Barr virus more sensitive to valganciclovir. Giving phenylbutyrate together with valganciclovir may block the growth of Epstein-Barr virus-infected cells and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving phenylbutyrate together with valganciclovir works in treating patients with relapsed or refractory Epstein-Barr virus-positive cancer.

NCT ID: NCT00376922 Completed - Pain Clinical Trials

Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases

Start date: June 2006
Phase: N/A
Study type: Interventional

RATIONALE: Listening to relaxing music during a bone marrow biopsy may be effective in reducing anxiety and pain. PURPOSE: This randomized clinical trial is studying how well music works in reducing anxiety and pain in adult patients undergoing bone marrow biopsy for hematologic cancers or other diseases.

NCT ID: NCT00324597 Active, not recruiting - Lung Cancer Clinical Trials

AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

Start date: October 2005
Phase: Phase 1
Study type: Interventional

RATIONALE: AMG 706 may stop the growth of cancer cells by blocking blood flow to the cancer or by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving AMG 706 together with gemcitabine may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of AMG 706 when given together with gemcitabine in treating patients with advanced solid tumors or lymphoma.

NCT ID: NCT00278200 Terminated - Clinical trials for Lymphoproliferative Disorder

Vaccine Therapy For Patients Being Considered For Organ Transplant Who Are at Risk For PTLD

Start date: January 2003
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines made from a person's white blood cells may help the body build an effective immune response. PURPOSE: This phase I trial is studying the side effects of vaccine therapy in treating patients who are being considered for solid organ transplant who are at risk for post-transplant lymphoproliferative disorder.

NCT ID: NCT00255749 Completed - Lymphoma Clinical Trials

Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer

Start date: August 2005
Phase: Phase 2
Study type: Interventional

RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia caused by cancer and chemotherapy. PURPOSE: This randomized phase II trial is studying how well epoetin alfa works in treating patients with anemia who are undergoing chemotherapy for cancer.